Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 209

Similar articles for PubMed (Select 21402604)

1.

Cost implications of the rapid adoption of newer technologies for treating prostate cancer.

Nguyen PL, Gu X, Lipsitz SR, Choueiri TK, Choi WW, Lei Y, Hoffman KE, Hu JC.

J Clin Oncol. 2011 Apr 20;29(12):1517-24. doi: 10.1200/JCO.2010.31.1217. Epub 2011 Mar 14.

2.

The adoption of new adjuvant radiation therapy modalities among Medicare beneficiaries with breast cancer: clinical correlates and cost implications.

Roberts KB, Soulos PR, Herrin J, Yu JB, Long JB, Dostaler E, Gross CP.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1186-92. doi: 10.1016/j.ijrobp.2012.10.009. Epub 2012 Nov 20.

3.

Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy.

Goldin GH, Sheets NC, Meyer AM, Kuo TM, Wu Y, Stürmer T, Godley PA, Carpenter WR, Chen RC.

JAMA Intern Med. 2013 Jun 24;173(12):1136-43. doi: 10.1001/jamainternmed.2013.1020.

PMID:
23689844
5.

Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer.

Ramsay C, Pickard R, Robertson C, Close A, Vale L, Armstrong N, Barocas DA, Eden CG, Fraser C, Gurung T, Jenkinson D, Jia X, Lam TB, Mowatt G, Neal DE, Robinson MC, Royle J, Rushton SP, Sharma P, Shirley MD, Soomro N.

Health Technol Assess. 2012;16(41):1-313. doi: 10.3310/hta16410. Review.

6.

Costs of radical prostatectomy for prostate cancer: a systematic review.

Bolenz C, Freedland SJ, Hollenbeck BK, Lotan Y, Lowrance WT, Nelson JB, Hu JC.

Eur Urol. 2014 Feb;65(2):316-24. doi: 10.1016/j.eururo.2012.08.059. Epub 2012 Sep 5. Review.

PMID:
22981673
7.

An economic analysis of conservative management versus active treatment for men with localized prostate cancer.

Perlroth DJ, Bhattacharya J, Goldman DP, Garber AM.

J Natl Cancer Inst Monogr. 2012 Dec;2012(45):250-7. doi: 10.1093/jncimonographs/lgs037.

8.

Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation.

Hummel S, Simpson EL, Hemingway P, Stevenson MD, Rees A.

Health Technol Assess. 2010 Oct;14(47):1-108, iii-iv. doi: 10.3310/hta14470. Review.

9.

Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.

Forsythe K, Blacksburg S, Stone N, Stock RG.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):630-5. doi: 10.1016/j.ijrobp.2011.06.2013. Epub 2011 Nov 16.

PMID:
22099032
10.

The potential impact of comparative effectiveness research on U.S. health care expenditures.

Perlroth DJ, Goldman DP, Garber AM.

Demography. 2010;47 Suppl:S173-90.

PMID:
21302424
11.

A nationwide charge comparison of the principal treatments for early stage prostate carcinoma.

Brandeis J, Pashos CL, Henning JM, Litwin MS.

Cancer. 2000 Oct 15;89(8):1792-9.

PMID:
11042575
12.

Treatment-related complications of radiation therapy after radical prostatectomy: comparative effectiveness of intensity-modulated versus conformal radiation therapy.

Crandley EF, Hegarty SE, Hyslop T, Wilson DD, Dicker AP, Showalter TN.

Cancer Med. 2014 Apr;3(2):397-405. doi: 10.1002/cam4.205. Epub 2014 Feb 12.

13.

Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse.

Jacobs BL, Zhang Y, Skolarus TA, Hollenbeck BK.

Health Aff (Millwood). 2012 Apr;31(4):750-9. doi: 10.1377/hlthaff.2011.1062.

14.

Certificate of need programs, intensity modulated radiation therapy use and the cost of prostate cancer care.

Khanna A, Hu JC, Gu X, Nguyen PL, Lipsitz S, Palapattu GS.

J Urol. 2013 Jan;189(1):75-9. doi: 10.1016/j.juro.2012.08.181. Epub 2012 Nov 16.

PMID:
23164382
15.

Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer.

Shah C, Lanni TB Jr, Ghilezan MI, Gustafson GS, Marvin KS, Ye H, Vicini FA, Martinez AA.

Brachytherapy. 2012 Nov-Dec;11(6):441-5. doi: 10.1016/j.brachy.2012.04.002. Epub 2012 Jun 23.

PMID:
22728157
16.

Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis.

Cooperberg MR, Ramakrishna NR, Duff SB, Hughes KE, Sadownik S, Smith JA, Tewari AK.

BJU Int. 2013 Mar;111(3):437-50. doi: 10.1111/j.1464-410X.2012.11597.x. Epub 2012 Dec 28.

17.

Costs of medical care after open or minimally invasive prostate cancer surgery: a population-based analysis.

Lowrance WT, Eastham JA, Yee DS, Laudone VP, Denton B, Scardino PT, Elkin EB.

Cancer. 2012 Jun 15;118(12):3079-86. doi: 10.1002/cncr.26609. Epub 2011 Oct 24.

18.

Examining the cost-effectiveness of radiation therapy among older women with favorable-risk breast cancer.

Sen S, Wang SY, Soulos PR, Frick KD, Long JB, Roberts KB, Yu JB, Evans SB, Chagpar AB, Gross CP.

J Natl Cancer Inst. 2014 Mar;106(3):dju008. doi: 10.1093/jnci/dju008. Epub 2014 Mar 5.

19.

The impact of technology diffusion on treatment for prostate cancer.

Schroeck FR, Kaufman SR, Jacobs BL, Zhang Y, Weizer AZ, Montgomery JS, Gilbert SM, Strope SA, Hollenbeck BK.

Med Care. 2013 Dec;51(12):1076-84. doi: 10.1097/MLR.0000000000000019.

20.

Use of advanced treatment technologies among men at low risk of dying from prostate cancer.

Jacobs BL, Zhang Y, Schroeck FR, Skolarus TA, Wei JT, Montie JE, Gilbert SM, Strope SA, Dunn RL, Miller DC, Hollenbeck BK.

JAMA. 2013 Jun 26;309(24):2587-95. doi: 10.1001/jama.2013.6882.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk